Ziopharm Oncology Profit Margin

The latest profit margin for ZIOP is -136966.67% as of March 2026. That compares with 131683.33% in the prior-year period — down 204.0% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Ziopharm Oncology's historical trend and sector peers before judging valuation or financial health.

Over the past year, ZIOP's profit margin moved from 131683.33% to -136966.67% — a 204.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Ziopharm Oncology's valuation or profitability profile.

Against Healthcare companies, ZIOP currently prints -136966.67% for profit margin, while the sector average sits near 14.34%. That is roughly 954918.8% below the sector mean. Large gaps often invite a closer look at Ziopharm Oncology's growth, margins, and balance sheet.

Profit Margin shows how effectively Ziopharm Oncology converts resources into returns. At -136966.67%, ZIOP may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 131683.33% in the prior-year period — down 204.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ZIOP's profit margin (-136966.67%), review year-over-year change from 131683.33%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.